Autoantibodies directed against the amino-terminal domain I of human calpastatin (ACAST-DI Ab) in connective tissue diseases. High levels of ACAST-DI Ab are associated with vasculitis in lupus

Saulot, Vincent; Vittecoq, Olivier; Salle, V.; Drouot, Laurent; Legoedec, J; Loët, Xavier Le; Godin, Michel; Ducroix, J.P.; Ménard, Jean-François; Tron, François; Gilbert, Danièle

doi:10.1006/jaut.2002.0598

Cited by 6 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, anti-calpastatin antibody was positive in 26% of psoriasis with a similar frequency in psoriasis vulgaris, psoriatic arthritis and generalized pustular psoriasis. This prevalence of anti-calpastatin antibody was comparable with that in RA (38%) and also that in other systemic autoimmune diseases (10-38%) [18,20,21,23]. Remarkably, anti-calpastatin antibody in psoriasis patients was able to block the inhibitory activity of calpastatin for calpain protease activity to a similar level of RA patients.…”

Section: Discussionsupporting

confidence: 64%

“…Autoantibodies directed against calpastatin are recently identified autoantibodies that are detected initially in 10–57% of sera from patients with rheumatoid arthritis (RA) [18–21]. In RA, anti‐calpastatin antibodies may contribute to the development of arthritis by enhancing the calpain activity as calpain functions as a proteoglycanase in cartilage destruction [22].…”

Section: Introductionmentioning

confidence: 99%

“…In RA, anti‐calpastatin antibodies may contribute to the development of arthritis by enhancing the calpain activity as calpain functions as a proteoglycanase in cartilage destruction [22]. However, anti‐calpastatin antibody is also detected in other various autoimmune disorders, including systemic sclerosis (38%), systemic lupus erythematosus (10–27%), polymyositis/dermatomyositis (24%), Sjögren's syndrome (19%) and overlap syndrome (29%) [18,20,21,23]. These findings suggest that anti‐calpastatin antibody is not disease‐specific, but contributes to inflammation associated with various autoimmune diseases.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Autoantibodies directed against the protease inhibitor calpastatin in psoriasis

Matsushita

Shimada

Kawara

et al. 2004

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryPsoriasis is believed to be a T cell-mediated autoimmune disease, but also exhibits autoantibody production. Calpastatin is an endogenous inhibitor of calpain, a ubiquitous protease that regulates inflammatory processes. Anticalpastatin autoantibody was first identified as an autoantibody specific to rheumatoid arthritis, but has been also detected in other autoimmune diseases. In this study, we examined the presence and levels of anti-calpastatin antibody in 77 psoriasis patients by enzyme-linked immunosorbent assay. Compared with normal controls, psoriasis patients exhibited significantly elevated IgG anti-calpastatin antibody levels that were similar to those found in rheumatoid arthritis patients. Remarkably, IgG anti-calpastatin autoantibody in sera from psoriasis patients inhibited calpastatin activity. Calpain II expression was up-regulated in psoriasis skin lesions compared with normal skin while calpastatin expression was normal. The results of this study reveal the presence of anti-calpastatin autoantibody in psoriasis.

show abstract

Section: Discussionsupporting

confidence: 64%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Autoantibodies directed against the protease inhibitor calpastatin in psoriasis

Matsushita

Shimada

Kawara

et al. 2004

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…12 In addition, there are new postulated target antigens for the development of vasculitis in lupus. 13 The evidence for the pathogenetic role of ANCA in the systemic vasculitides has not been corroborated speci cally for patients with SLE.…”

Section: The Pathogenetic Role Of Anca In Vasculitismentioning

confidence: 99%

Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus

Sen

Isenberg

2003

Lupus

View full text Add to dashboard Cite

Although antineutrophil cytoplasmic antibodies (ANCA) were first associated with the primary vasculitides, it is now clear that 15-20% of patients with lupus have detectable ANCA. In this short review we confirm that the major link is with perinuclear ANCA (pANCA) but not cytoplasmic ANCA (cANCA). ANCA to myeloperoxidase are associated with drug-induced lupus. There may be a link between pANCA levels and disease activity in some patients although the links to specific organ involvement are not proven. ANCA in lupus must be interpreted cautiously with particular attention paid to laboratory technique, the size, age and genetic background of the populations studied.

show abstract

“…The presence of autoantibodies in patient sera with rheumatoid arthritis (RA) can precede onset of the disease and thus be predictive of the development of RA. Rheumatoid factor is one of these autoantibodies, and other autoantibodies have been described, such as autoantibodies directed against citrullinated peptides, α‐enolase, Sa, calpastatin, BiP, and glucose‐6 phosphate isomerase 1–8 . However, these autoantibodies are positive in only 50–60% of RA patients at onset of disease and even less before the onset of any RA symptoms 9–12 …”

Section: Introductionmentioning

confidence: 99%

A New Target for Autoantibodies in Patients with Rheumatoid Arthritis

Robert-Pachot

Desbos

Moreira

et al. 2007

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Early treatment of rheumatoid arthritis (RA) with disease-modifying antirheumatic drugs can achieve a better disease outcome and reduce the severity of joint damage. The presence of autoantibodies in patient sera can precede onset of the disease and thus be predictive of the development of RA. To date, known autoantibodies in RA are positive in only 50-60% of RA patients at onset of disease and even less before the onset of any RA symptom. The aim of this study was to identify new antibodies that could be useful for the diagnosis of RA using synovial membrane proteins, which represent the best source of candidate RA autoantigens. The humoral reactivity of sera from RA patients was explored using immunoblotting on extracted proteins obtained from synovial membranes from RA after synovectomy or arthroplasty. A new target protein with a molecular weight of 26 kDa was found to be recognized by autoantibodies in RA sera. This protein was identified using MALDI-TOF mass spectrometry and two-dimensional electrophoresis as carbonic anhydrase III with a high level of confidence. In conclusion, this study demonstrates new autoantibodies in RA patients that are directed against carbonic anhydrase III. The sensitivity and specificity of these new autoantibodies for RA have to be further evaluated.

show abstract

Autoantibodies directed against the amino-terminal domain I of human calpastatin (ACAST-DI Ab) in connective tissue diseases. High levels of ACAST-DI Ab are associated with vasculitis in lupus

Cited by 6 publications

References 17 publications

Autoantibodies directed against the protease inhibitor calpastatin in psoriasis

Autoantibodies directed against the protease inhibitor calpastatin in psoriasis

Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus

A New Target for Autoantibodies in Patients with Rheumatoid Arthritis

Contact Info

Product

Resources

About